Research
Hormonal
Semaglutide improves glycemic control and metabolic parameters in patients with Type 2 Diabetes and obesity.
For those with Type 2 Diabetes, semaglutide helps manage blood sugar and aids in weight loss, though the weight loss effect may be more modest compared to non-diabetic patients.
GoodSupportsHIGH confidence
STEP 2 Trial... Improved glycemic control + modest weight loss... Effective for diabetes with metabolic benefits.
Why this rating
Based on STEP 2 trial data cited in the review.
Source
Semaglutide as a Cornerstone Therapy in Obesity: Clinical and Pharmacological Insights
Sagarika Basavaraj et al. · Journal of Pharmaceutical Research · 2026
DOI 10.18579/jopcr/v25.i1.10
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →